Development of leading first-generation vaccines against SARS-CoV-2

SARS-CoV-2 has infected more than 167 million individuals globally. Highly effective and safe vaccines are required to accelerate the development of herd immunity to end the pandemic. This review focuses on vaccines that are being developed at unprecedented speed globally and are completing late pha...

Descripción completa

Detalles Bibliográficos
Autores principales: Perera, Pin-Yu, Perera, Liyanage P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8133830/
https://www.ncbi.nlm.nih.gov/pubmed/34022375
http://dx.doi.org/10.1016/j.micinf.2021.104841
_version_ 1783695128735514624
author Perera, Pin-Yu
Perera, Liyanage P.
author_facet Perera, Pin-Yu
Perera, Liyanage P.
author_sort Perera, Pin-Yu
collection PubMed
description SARS-CoV-2 has infected more than 167 million individuals globally. Highly effective and safe vaccines are required to accelerate the development of herd immunity to end the pandemic. This review focuses on vaccines that are being developed at unprecedented speed globally and are completing late phase clinical trials to meet this urgent need.
format Online
Article
Text
id pubmed-8133830
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-81338302021-05-20 Development of leading first-generation vaccines against SARS-CoV-2 Perera, Pin-Yu Perera, Liyanage P. Microbes Infect Article SARS-CoV-2 has infected more than 167 million individuals globally. Highly effective and safe vaccines are required to accelerate the development of herd immunity to end the pandemic. This review focuses on vaccines that are being developed at unprecedented speed globally and are completing late phase clinical trials to meet this urgent need. Elsevier 2021 2021-05-20 /pmc/articles/PMC8133830/ /pubmed/34022375 http://dx.doi.org/10.1016/j.micinf.2021.104841 Text en Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Perera, Pin-Yu
Perera, Liyanage P.
Development of leading first-generation vaccines against SARS-CoV-2
title Development of leading first-generation vaccines against SARS-CoV-2
title_full Development of leading first-generation vaccines against SARS-CoV-2
title_fullStr Development of leading first-generation vaccines against SARS-CoV-2
title_full_unstemmed Development of leading first-generation vaccines against SARS-CoV-2
title_short Development of leading first-generation vaccines against SARS-CoV-2
title_sort development of leading first-generation vaccines against sars-cov-2
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8133830/
https://www.ncbi.nlm.nih.gov/pubmed/34022375
http://dx.doi.org/10.1016/j.micinf.2021.104841
work_keys_str_mv AT pererapinyu developmentofleadingfirstgenerationvaccinesagainstsarscov2
AT pereraliyanagep developmentofleadingfirstgenerationvaccinesagainstsarscov2

Ejemplares similares